(WFRF:(Rademaker Havinga T))
Search: (WFRF:(Rademaker Havinga T)) > Modifying effect of...
- 1 of 1
- Previous record
- Next record
- To hitlist
- Camenzind, E (author)
Modifying effect of dual antiplatelet therapy on incidence of stent thrombosis according to implanted drug-eluting stent type
- Article/chapterEnglish2014
Publisher, publication year, extent ...
- 2014-03-13
- Oxford University Press (OUP),2014
- printrdacarrier
Numbers
- LIBRIS-ID:oai:DiVA.org:uu-245829
- https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-245829URI
- https://doi.org/10.1093/eurheartj/ehu084DOI
Supplementary language notes
- Language:English
- Summary in:English
Part of subdatabase
- SwePubSwePub
Classification
Notes
- AIM: To investigate the putative modifying effect of dual antiplatelet therapy (DAPT) use on the incidence of stent thrombosis at 3 years in patients randomized to Endeavor zotarolimus-eluting stent (E-ZES) or Cypher sirolimus-eluting stent (C-SES). METHODS AND RESULTS: Of 8709 patients in PROTECT, 4357 were randomized to E-ZES and 4352 to C-SES. Aspirin was to be given indefinitely, and clopidogrel/ticlopidine for >/= 3 months or up to 12 months after implantation. Main outcome measures were definite or probable stent thrombosis at 3 years. Multivariable Cox regression analysis was applied, with stent type, DAPT, and their interaction as the main outcome determinants. Dual antiplatelet therapy adherence remained the same in the E-ZES and C-SES groups (79.6% at 1 year, 32.8% at 2 years, and 21.6% at 3 years). We observed a statistically significant (P = 0.0052) heterogeneity in treatment effect of stent type in relation to DAPT. In the absence of DAPT, stent thrombosis was lower with E-ZES vs. C-SES (adjusted hazard ratio 0.38, 95% confidence interval 0.19, 0.75; P = 0.0056). In the presence of DAPT, no difference was found (1.18; 0.79, 1.77; P = 0.43). CONCLUSION: A strong interaction was observed between drug-eluting stent type and DAPT use, most likely prompted by the vascular healing response induced by the implanted DES system. These results suggest that the incidence of stent thrombosis in DES trials should not be evaluated independently of DAPT use, and the optimal duration of DAPT will likely depend upon stent type (Clinicaltrials.gov number NCT00476957).
Subject headings and genre
Added entries (persons, corporate bodies, meetings, titles ...)
- Boersma, E (author)
- Wijns, W (author)
- Mauri, L (author)
- Rademaker-Havinga, T (author)
- Ordoubadi, F F (author)
- Suttorp, M J (author)
- Al Kurdi, M (author)
- Steg, P G (author)
- Wallentin, Lars (author)
Related titles
- In:European Heart Journal: Oxford University Press (OUP)35:29, s. 1932-19480195-668X1522-9645
Internet link
Find in a library
- European Heart Journal (Search for host publication in LIBRIS)
To the university's database
- 1 of 1
- Previous record
- Next record
- To hitlist
Find more in SwePub
- By the author/editor
- Camenzind, E
- Boersma, E
- Wijns, W
- Mauri, L
- Rademaker-Having ...
- Ordoubadi, F F
- show more...
- Suttorp, M J
- Al Kurdi, M
- Steg, P G
- Wallentin, Lars
- show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
- MEDICAL AND HEAL ...
- and Clinical Medicin ...
- and Cardiac and Card ...
- Articles in the publication
- European Heart J ...
- By the university
- Uppsala University
Search outside SwePub
- Extend your search to:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - National Library Systems
- LIBRIS.kb.se
